Clusterin, paraoxonase 1, and myeloperoxidase alterations induce high‐density lipoproteins dysfunction and contribute to peripheral artery disease; aggravation by type 2 diabetes mellitus

• Published in: BioFactors (Oxford) Vol. 48; no. 2; pp. 454 - 468
• Main Authors: Sanda, Gabriela M., Toma, Laura, Barbalata, Teodora, Moraru, Oriana E., Niculescu, Loredan S., Sima, Anca V., Stancu, Camelia S.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.03.2022
• Subjects: Aryldialkylphosphatase - genetics; Aryldialkylphosphatase - metabolism; clusterin; Clusterin - genetics; Clusterin - metabolism; diabetes; Diabetes Mellitus, Type 2 - metabolism; Endothelial Cells - metabolism; high‐density lipoproteins; Humans; Lipoproteins, HDL; myeloperoxidase; paraoxonase 1; Peripheral Arterial Disease; peripheral artery disease; Peroxidase - genetics; Peroxidase - metabolism; paraoxonase 1; clusterin; myeloperoxidase; peripheral artery disease; high-density lipoproteins; diabetes
• ISSN: 0951-6433; 1872-8081; 1872-8081
• DOI: 10.1002/biof.1800

Peripheral artery disease (PAD) is an atherosclerotic disorder affecting arteries of the lower limbs, the major risk factors including dyslipidemia and diabetes mellitus (DM). We aimed to identify alterations of the proteins in high‐density lipoproteins (HDL) associated with HDL dysfunction in PAD patients. HDL2 and HDL3 were isolated from plasma of PAD patients with/without DM (PAD‐DM/PAD) and healthy subjects (N). Apolipoprotein AI (ApoAI), ApoAII, ApoCIII, clusterin (CLU), paraoxonase 1 (PON1), myeloperoxidase (MPO), and ceruloplasmin (CP) were measured in HDL2/HDL3 and plasma. Oxidation and glycation of the analyzed proteins were assessed as malondialdehyde‐protein adducts (MDA) and advanced glycation end‐products (AGE), respectively. The anti‐inflammatory effect of HDL3 was estimated as its potential to reduce monocyte adhesion to tumor necrosis factor α‐activated endothelial cells. We show that in PAD patients compared to N subjects: (i) HDL2 presented increased levels of MDA‐PON1, AGE‐PON1, AGE‐ApoAI, ApoAII, ApoCIII, and CP levels, and decreased PON1 levels; (ii) HDL3 had increased levels of MDA‐ and AGE‐CLU and ‐ApoAI, MDA‐PON1, ApoCIII, CLU, MPO, CP, and reduced PON1 levels. All these alterations were exacerbated by DM. These changes were more pronounced in HDL3, which had reduced anti‐inflammatory potential in PAD and became pro‐inflammatory in PAD‐DM. In PAD patients' plasma, CLU levels and MPO specific activity increased, while PON1 specific activity decreased. In conclusion, HDL function is altered in PAD patients due to multiple modifications of associated proteins that are aggravated by DM. Plasma CLU, MPO, and PON1 could constitute indicators of HDL dysfunction and contribute to risk stratification in PAD patients.